Company Overview
- Website
- prevailtherapeutics.com
- Employees
- 32
- Founded in
- 2017
- Industry
- BioTech/Drugs
- Stock Symbol
- NASDAQ:PRV
- SIC Code
-
8731 - Commercial Physical and Biological Research
Financials & Stats
Revenue
$50B
Recent News & Media
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
- May 5, 2025
- businesswire.com
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
- Apr 28, 2025
- businesswire.com
Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal
- Apr 3, 2025
- fiercebiotech.com
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
- Jan 13, 2025
- businesswire.com
Prevail Therapeutics Seeking to Bring Gene Therapy PR001 to Parkinson Disease With Phase 1/2a PROPEL Clinical Trial
- Dec 16, 2024
- cgtlive.com
Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
- Oct 9, 2024
- prnewswire.com
Who is Prevail Therapeutics
Prevail Therapeutics, a company based in New York City, is a subsidiary of Eli Lilly and Company. Founded in 2017, the company focuses its efforts on developing novel gene therapies to address the root genetic causes of Parkinson's disease and other neurodegenerative disorders. With 32 employees, Prevail Therapeutics has generated approximately $50 million in revenue. The company's therapies aim to slow or halt the progression of these debilitating diseases. They utilize a precision medicine approach, targeting specific patient populations with urgent needs where existing therapies are insufficient to modify the course of their conditions. Prevail Therapeutics emphasizes its commitment to scientific rigor, collaboration, integrity, and agility. The company prides itself on building a team of dedicated and talented individuals who share their passion for serving patients with neurodegenerative diseases. For more information, please visit the Eli Lilly and Company website at www.lilly.com.
Company Leadership
Prevail Therapeutics Industry Tags
Companies Similar to Prevail Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Prevail Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 50M | Cambridge, MA | |||
| 50M | 24 | Cambridge, MA | ||
| 50M | 68 | Cambridge, MA | 2000 | |
| 50M | 7 | Boston, MA | 2006 | |
| 50M | 225 | Boston, MA | 2002 |